Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
| Revenue (TTM) | $29.74B |
| Gross Profit (TTM) | $23.60B |
| EBITDA | $14.74B |
| Operating Margin | 39.30% |
| Return on Equity | 43.40% |
| Return on Assets | 13.30% |
| Revenue/Share (TTM) | $23.92 |
| Book Value | $18.93 |
| Price-to-Book | 6.89 |
| Price-to-Sales (TTM) | 5.61 |
| EV/Revenue | 5.94 |
| EV/EBITDA | 12.19 |
| Quarterly Earnings Growth (YoY) | 54.80% |
| Quarterly Revenue Growth (YoY) | 4.40% |
| Shares Outstanding | $1.24B |
| Float | $1.24B |
| % Insiders | 0.12% |
| % Institutions | 94.27% |
Volatility is currently contracting
GILD heads into Q2 earnings with HIV franchise strength, rising Yeztugo expectations and oncology progress, even as Cell Therapy faces competitive pressure.
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GILD's HIV franchise gains momentum with strong Biktarvy and Descovy demand, Yeztugo growth and a promising pipeline targeting long-term expansion.
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's second quarter 2026 financial results and provide a business update.A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one.
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer (NYSE:PFE | PFE Price Prediction) trades at $24.25, against a Wall Street consensus price target of $28.79, which represents implied upside of almost 19%.
On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.
Gilead wins FDA approval to expand Trodelvy into first-line mTNBC, boosting its market reach and strengthening its oncology growth strategy.
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GILD and any ticker you trade — then tracks every position and per-strategy win rate.
